{"schema_version":"secwatch.filing_event.v1","accession":"0001720580-26-000054","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2026-09-01T11:02:02+00:00","discovered_at":"2026-09-01T11:05:01.778572+00:00","generated_at":"2026-09-01T11:05:10.913828+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adicet completes prula-cel SLE study visits; topline due Sept 2026; ADI-212 IND cleared","bullets":["Prula-cel Phase 1 last patient visit completed; topline data from 22 SLE patients (13 with ≥12 mo follow-up) expected September 2026.","FDA cleared IND for ADI-212 in mCRPC; Phase 1 enrollment to start 4Q 2026.","Expanded prula-cel to outpatient setting after FDA alignment; systemic sclerosis update expected Q4 2026.","In vivo CAR-T platform: first candidate expected in clinic 2H 2027; programs target myeloma, NHL, solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001720580-26-000054","json":"https://secwatch.observer/filing/0001720580-26-000054.json","markdown":"https://secwatch.observer/filing/0001720580-26-000054.md","text":"https://secwatch.observer/filing/0001720580-26-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000054/0001720580-26-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000054/acet-20260901.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-01T11:05:10.913828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}